Table 2. Characteristics pertinent to the HF and HTx recipient groups.
| Variable | HFrEF | HTx (< 3 yrs) |
HTx (5-10 yrs) | HTx (> 14 yrs) |
|---|---|---|---|---|
| N = 14 | N = 12 | N = 12 | N = 11 | |
| Diagnosis (ischemic cardiomyopathy) | 7/14 | 7/12 | 6/12 | 6/11 |
| Diagnosis (non-ischemic cardiomyopathy) | 7/14 | 5/12 | 6/12 | 5/11 |
| Time post-HTx (months ± SE) | NA | 13 ± 4 (≈ 1 yr) | 85 ± 7 (≈ 7 yrs) | 226 ± 12 (≈ 19 yrs) |
| History of Rejection (# of all cases) | NA | 1/12 | 1/12 | 2/12 |
| Left Ventricular Ejection fraction (%) | 29 ± 4 | 66 ± 2* | 61 ± 2* | 61 ± 2* |
| Diabetic (# of all cases) | 6/14 | 7/12 | 3/12 | 6/11 |
| Medications: | ||||
| Cyclosporine (# of all cases) | 0/14 | 2/12 | 4/12 | 8/11 |
| Tacrolimus (# of all cases) | 0/14 | 10/12 | 7/12 | 2/11 |
| Azathioprine (# of all cases) | 0/14 | 2/12 | 2/12 | 0/11 |
| Mycophenolic acid (# of all cases) | 0/14 | 9/12 | 7/12 | 5/11 |
| Sirolimus (# of all cases) | 0/14 | 0/12 | 4/12 | 2/11 |
| Prednisone (# of all cases) | 0/14 | 6/12 | 2/12 | 4/11 |
| Beta-blocker (# of all cases) | 14/14 | 1/12 | 4/12 | 6/11 |
| ACE-Inhibitor (# of all cases) | 10/14 | 6/12 | 5/12 | 2/11 |
| Angiotensin Receptor Blocker (# of all cases) |
3/14 | 2/12 | 4/12 | 2/11 |
| Statin (# of all cases) | 11/14 | 10/12 | 9/12 | 5/11 |
| Diuretic (# of all cases) | 9/14 | 3/12 | 5/12 | 3/11 |
| Calcium channel-blocker (# of all cases) | 1/14 | 5/12 | 3/12 | 4/11 |
*
Mean ± SE; Significantly different from HFrEF